Warburg Pincus and Advent International earlier this week completed the carve-out of Baxter International’s BPS business for $4.25bn.
The post Warburg’s Ruoxi Chen: Innovative therapies will drive demand for Simtra BioPharma Solutions appeared first on PE Hub.
Powered by WPeMatico
Comments are closed.